Twist Bioscience Corporation TWST
132.13 USD -3.21 (-2.37%)
At closeNov 11, 2026, 8:37 AM EST
140.08 +7.95 +6.02%
Pre-market · Nov 11, 8:37 AM ET
125.58 Day range 138.06
23.30 52-week range 219.71
- YTD
- +316.55%
- 1 year
- +321.87%
News
businesswire.com Twist Bioscience to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that Emily M. Leproust, Ph.D., CEO and…
fool.com Meet the Unstoppable Vanguard ETF Beating the S&P 500 and the Dow Jones in 2026 Small-cap stocks have benefited from a range of tailwinds this year.
benzinga.com Twist Bioscience Stock Sinks as Bear Cave Raises Valuation Concerns Twist Bioscience Corp (NASDAQ:TWST) shares are plunging Thursday. The Bear Cave, which Hunterbrook Media owns, said that the life science tools company's stock price may have run ahead of its…
seekingalpha.com Polen 5Perspectives Growth Opportunities Q3 2026 Portfolio Review During the third quarter of 2026, the Polen 5Perspectives Growth Opportunities Composite Portfolio returned -6.2% net of fees compared to the 0.5% return of the Russell 3000 Growth Index. The top…
seekingalpha.com Polen 5Perspectives Small Growth Composite Q3 2026 Portfolio Attribution And Activity The top contributors to the Portfolio's relative performance in the quarter were Twist Bioscience, RingCentral, and Five9. The most significant detractors from the Portfolio's relative performance in…
benzinga.com Twist Bioscience Proposes Derivative Litigation Settlement Featuring Corporate Governance Reforms And $1M In Legal Fees SUMMARY NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTIONTO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF TWIST BIOSCIENCE CORPORATION ("TWIST" OR THE "COMPANY") COMMON STOCK AS OF OCTOBER 15,
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $190 TD Cowen analyst Brendan Smith maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $115 to $190.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205 Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $120 to $205.
benzinga.com Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
benzinga.com This Generac Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Overweight GNRC ($303), Buy ENTG ($200) and VYLR ($87), Neutral SPOT ($540).
benzinga.com Jefferies Initiates Coverage On Twist Bioscience with Hold Rating, Announces Price Target of $150 Jefferies analyst Matthew Stanton initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Hold rating and announces Price Target of $150.
benzinga.com Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215 Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $112 to $215.
benzinga.com Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
benzinga.com Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’ Cathie Wood defends ARKK's 15% drop vs QQQ's 112% 5-year gain, calling it an 'incorrect comparison' and blaming 'endpoint sensitivity.'
benzinga.com $1000 Invested In Twist Bioscience 5 Years Ago Would Be Worth This Much Today Twist Bioscience (NASDAQ:TWST) has outperformed the market over the past 5 years by 3.68% on an annualized basis producing an average annual return of 15.78%. Currently, Twist Bioscience has a market…- benzinga.com Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212 Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $107 to $212.
- benzinga.com Leerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190 Leerink Partners analyst Puneet Souda maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $160 to $190.
benzinga.com Twist Bioscience Stock Hits New High, Then Retreats: What's Happening? Twist Bioscience shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session.
benzinga.com Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.
benzinga.com Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem Twist Bioscience joins Eli Lilly's TuneLab platform, supplying high-throughput antibody data to train advanced AI drug prediction models.
benzinga.com LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.
benzinga.com BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45 BWS Financial analyst Hamed Khorsand initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Sell rating and announces Price Target of $45.
benzinga.com UBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144 UBS analyst Doug Schenkel initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Neutral rating and announces Price Target of $144.
benzinga.com Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report TWST shares surge after Anthropic names the company an independent evaluator in a new AI-driven protein design campaign. The bullish momentum overshadows a critical short report published on X by…
benzinga.com Twist Bioscience Stock Hits 52-Week High - Here's Why Twist Bioscience (TWST) stock jumped 17% after Anthropic chose the firm to test AI-designed proteins. Get the full market update.
benzinga.com Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.- benzinga.com Piper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115 Piper Sandler analyst David Westenberg maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $85 to $115.
- benzinga.com Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $115 Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $113 to $115.
benzinga.com Twist Bioscience Sees AI Drug Discovery Pipeline Expand Twist Bioscience (NASDAQ: TWST) stock is up on strong Q3 results and raised guidance. AI drug discovery and NGS businesses show growth.- benzinga.com Twist Bioscience Raises FY2026 Sales Guidance from $442.000M-$447.000M to $456.000M-$457.000M vs $446.103M Est Twist Bioscience (NASDAQ:TWST) raises FY2026 sales outlook from $442.000 million-$447.000 million to $456.000 million-$457.000 million vs $446.103 million estimate.
- benzinga.com Twist Bioscience Sees Q4 Sales $123.000M-$124.000M vs $117.546M Est Twist Bioscience (NASDAQ:TWST) sees Q4 sales of $123.000 million-$124.000 million vs $117.546 million analyst estimate.
- benzinga.com Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $120 Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $90 to $120.
benzinga.com Evercore ISI Group Downgrades Twist Bioscience to In-Line, Raises Price Target to $102 Evercore ISI Group analyst Vijay Kumar downgrades Twist Bioscience (NASDAQ:TWST) from Outperform to In-Line and raises the price target from $66 to $102.
benzinga.com Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $107 Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $60 to $107.- benzinga.com Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $95 Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $65 to $95.
- benzinga.com Twist Bioscience Files Prospectus For Offering Mixed Shelf; Terms Undisclosed https://www.sec.gov/Archives/edgar/data/1581280/000110465926075726/tm2617605-1_s3asr.htm
benzinga.com TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $89 TD Cowen analyst Brendan Smith maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $68 to $89.- benzinga.com Canaccord Genuity Initiates Coverage On Twist Bioscience with Buy Rating, Announces Price Target of $90 Canaccord Genuity analyst Kyle Mikson initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Buy rating and announces Price Target of $90.
- benzinga.com Piper Sandler Initiates Coverage On Twist Bioscience with Overweight Rating, Announces Price Target of $85 Piper Sandler analyst David Westenberg initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Overweight rating and announces Price Target of $85.
- benzinga.com LenioBio GmbH Partners With Twist Bioscience To Integrate Its ALiCE Platform With Twist's DNA Production, Automation Tools -LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will…
benzinga.com These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results Twist Bioscience Corp (TWST) reported Q2 loss but exceeded sales guidance. CEO expects profitability and raised FY sales guidance. Analysts raise price targets.
benzinga.com This UFP Industries Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday Top Wall Street analysts changed outlook on top names. Check analyst ratings page for full changes. See other analysts' views on UFPI, TWST, BMA, and PAC.
benzinga.com Crowdstrike To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday Top analysts change outlooks on top names: UBS raises price target for TD Synnex, BMO Capital raises target for Goldman Sachs, Citigroup raises target for Pinterest, and more.- benzinga.com Leerink Partners Upgrades Twist Bioscience to Outperform, Announces $70 Price Target Leerink Partners analyst Puneet Souda upgrades Twist Bioscience (NASDAQ:TWST) from Market Perform to Outperform and announces $70 price target.
- benzinga.com Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $65 Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $55 to $65.
- benzinga.com Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $60 Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $55 to $60.
- benzinga.com Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $65 Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $50 to $65.
benzinga.com AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens Twist Bioscience posts wider Q2 loss, beats revenue estimates, raises FY26 outlook, and expands gene portfolio.